Homepage
Catalog of Screening Compounds
Screening Libraries
Focused and Target Libraries
Active Reference Sets
Diversity Libraries
Screening Compounds
Building blocks
Drug Discovery Services
Custom Chemistry
Medicinal chemistry
In silico Drug Design (CADD)
Discovery Biology
Animal Models
Toxicology and Safety
ADME, DMPK
Chemistry, Manufacturing and Controls
Company
News & Media
Contact us
For suppliers
Trends in discovery compounds
Homepage
>
Company
>
Media
>
Pharma News
>
2025
Pharma News, 2025
IMPACT
IMPACT ovarian cancer capsules authorised in China
FDA beats EMA
FDA beats EMA to most approved new drugs in 2024
Amgen’s Lumakras/Vectibix
Amgen’s Lumakras/Vectibix approved by FDA to treat metastatic colorectal cancer
Antibiotic treatment
Antibiotic treatment for drug-resistant tuberculosis found to be safe and effective in clinical trial
FDA clears Axcynsis’ AT03-65 IND
FDA clears Axcynsis’ AT03-65 IND for CLDN6-positive solid tumours
Immune complex removes receptors
Immune complex removes receptors from stem cells to protect against cancer, preclinical study finds
JP Morgan 2025
JP Morgan 2025: AbbVie counts on Skyrizi and Rinvoq to fill Humira-sized hole
Lilly gains US FDA
Lilly gains US FDA approval for Omvoh to treat Crohn’s disease
BBO-8520
BBO-8520 Receives Fast Track Designation for NSCLC Treatment
Eterna
Eterna Therapeutics Announces Positive Preclinical Study Results on Lead Product ERNA-101 in Ovarian Cancer
2025 R&D layoffs
Despite another solid national jobs report in December 2024—256,000 new payroll jobs and a steady 4.1% unemployment rate—companies in research-intensive fields have continued to trim their wor...
India Genome Project
India Genome Project: After mapping 10,000 healthy genomes, India targets cancer DNA next
48
49
50
51
52
53
54
